Creative Medical Technology (NASDAQ:CELZ) Announces Quarterly Earnings Results, Misses Expectations By $0.49 EPS

Creative Medical Technology (NASDAQ:CELZ) posted its quarterly earnings results on Friday. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.49), Zacks reports.

Creative Medical Technology Trading Up 9.0 %

NASDAQ CELZ traded up $0.27 during trading on Friday, hitting $3.27. 155,226 shares of the company’s stock were exchanged, compared to its average volume of 37,240. The company has a market cap of $7.60 million, a PE ratio of -0.86 and a beta of 1.70. Creative Medical Technology has a fifty-two week low of $1.96 and a fifty-two week high of $6.90. The stock’s 50 day moving average price is $3.69 and its two-hundred day moving average price is $3.28.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.